Biohaven Pharmaceutical (NYSE:BHVN) received a $75.00 price objective from analysts at Piper Jaffray Companies in a report released on Monday. The brokerage currently has a “buy” rating on the stock. Piper Jaffray Companies’ price objective would indicate a potential upside of 50.12% from the company’s previous close.

BHVN has been the subject of a number of other research reports. Cantor Fitzgerald boosted their target price on Biohaven Pharmaceutical to $82.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a report on Tuesday, January 15th. Oppenheimer set a $63.00 target price on Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Monday, December 10th. Needham & Company LLC reiterated a “buy” rating and set a $56.00 target price (up previously from $48.00) on shares of Biohaven Pharmaceutical in a report on Monday, March 4th. Finally, ValuEngine upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $54.11.

Shares of NYSE:BHVN traded up $0.52 during trading on Monday, reaching $49.96. 305,004 shares of the stock were exchanged, compared to its average volume of 445,852. Biohaven Pharmaceutical has a 12-month low of $16.50 and a 12-month high of $50.65. The stock has a market capitalization of $2.22 billion, a P/E ratio of -8.14 and a beta of 0.46.

In other Biohaven Pharmaceutical news, insider John Tilton sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, January 10th. The stock was sold at an average price of $37.67, for a total value of $395,535.00. Following the completion of the transaction, the insider now owns 10,500 shares in the company, valued at approximately $395,535. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Vlad Coric sold 100,000 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $50.09, for a total value of $5,009,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 304,180 shares of company stock valued at $14,505,289. 34.20% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Flinton Capital Management LLC purchased a new position in Biohaven Pharmaceutical in the 4th quarter worth approximately $42,000. Neuburgh Advisers LLC purchased a new position in shares of Biohaven Pharmaceutical during the 4th quarter valued at approximately $52,000. Tower Research Capital LLC TRC boosted its stake in shares of Biohaven Pharmaceutical by 602.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,057 shares of the company’s stock valued at $190,000 after buying an additional 4,337 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Biohaven Pharmaceutical by 14.1% during the 4th quarter. Legal & General Group Plc now owns 5,284 shares of the company’s stock valued at $196,000 after buying an additional 652 shares during the last quarter. Finally, Shell Asset Management Co. purchased a new position in shares of Biohaven Pharmaceutical during the 3rd quarter valued at approximately $205,000. Hedge funds and other institutional investors own 88.91% of the company’s stock.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.

Featured Article: How Do You Calculate Return on Investment (ROI)?

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.